<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04947176</url>
  </required_header>
  <id_info>
    <org_study_id>201339</org_study_id>
    <nct_id>NCT04947176</nct_id>
  </id_info>
  <brief_title>C15:0 Supplementation in Young Adults at Risk for Metabolic Syndrome</brief_title>
  <official_title>A Double Blind, Randomized, Single Center, Controlled, Two Arm Trial of Dietary C15:0 Supplementation in Young Adults at Risk for Metabolic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jeffrey B. Schwimmer, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine changes in plasma C15:0 levels in young adults with BMI ≥ 25 in&#xD;
      response to 12 weeks of daily oral C15:0 supplementation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Metabolic syndrome is a disturbance in how the body processes both carbohydrates and fats.&#xD;
      This condition has become common in children and young adults, especially in association with&#xD;
      excess body fat. People with metabolic syndrome are at increased risk for type 2 diabetes,&#xD;
      cardiovascular disease, and nonalcoholic fatty liver disease (NAFLD). Diet is believed to&#xD;
      play an important role in both developing and treating metabolic syndrome. Studies have shown&#xD;
      that low dietary intake of a type of fats known as odd chain fatty acids is associated with a&#xD;
      higher risk for each of the metabolic syndrome associated conditions of diabetes, heart&#xD;
      disease, and liver disease. Supplementation with one specific odd chain fatty acid known as&#xD;
      C15:0 has shown to decrease the effects of metabolic syndrome in both cellular and animal&#xD;
      models. In people, the epidemiology of consumption of C15:0 in the diet is consistent with&#xD;
      this belief. However, clinical trials have yet to be done with supplemental C15:0. This study&#xD;
      is a pilot study of C15:0 supplementation in a group of young adults at risk for metabolic&#xD;
      syndrome. The study will determine how well supplementation with C15:0 daily for 12 weeks is&#xD;
      able to raise levels of C15:0 in the blood when compared to placebo. The study will also look&#xD;
      for signs that increasing blood levels of C15:0 leads to changes in physiology.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 6, 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in plasma C15:0 levels</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>To determine changes in plasma C15:0 levels in response to daily supplementation of C15:</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>To assess safety and tolerability of C15:0 supplementation as measured by number of participants with treatment-related adverse events as assessed by CTCAE v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Weight</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>Change in Weight (kg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in BMI</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>Change in BMI (kg/m^2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum alanine aminotransferase</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>Change in serum alanine aminotransferase (U/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum aspartate aminotransferase</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>Change in serum aspartate aminotransferase (U/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum glutamyl transpeptidase</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>Change in serum glutamyl transpeptidase (U/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum total cholesterol</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>Change in serum total cholesterol (mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum LDL-cholesterol</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>Change in serum LDL-cholesterol (mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum HDL-cholesterol</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>Change in serum HDL-cholesterol (mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in High Sensitivity C-reactive protein</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>Change in High Sensitivity C-reactive protein (mg/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum glucose</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>Change in serum glucose (mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum insulin</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>Change in serum insulin (μIU/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hemoglobin</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>Change in hemoglobin (mg/dL)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>200mg of pentadecanoic acid (C15:0) supplementation in capsules form</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo in capsules form</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Supplement</intervention_name>
    <description>200mg C15:0 once daily</description>
    <arm_group_label>Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 through 25 years&#xD;
&#xD;
          -  Body Mass Index ≥ 25 Kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Reported habitual dietary intake of C15:0 that consistently exceeds 250 mg per day&#xD;
&#xD;
          -  Significant alcohol consumption (average consumption &gt;1 drink/day for females, &gt;2&#xD;
             drink/day for males or episodes of binge drinking &gt;5 drinks/day)&#xD;
&#xD;
          -  Inability to swallow capsules&#xD;
&#xD;
          -  Type 1 or Type 2 Diabetes&#xD;
&#xD;
          -  Liver Cirrhosis&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Body weight greater than 125 kg at screening&#xD;
&#xD;
          -  LDL-cholesterol &gt; 160 mg/dL&#xD;
&#xD;
          -  Triglycerides &gt; 500 mg/dL&#xD;
&#xD;
          -  Hemoglobin &lt; 10.0 gm/dL&#xD;
&#xD;
          -  Current Omega 3 Fatty Acid supplement usage&#xD;
&#xD;
          -  Current use of Statin medications&#xD;
&#xD;
          -  Any other condition which, in the opinion of the investigator, would impede compliance&#xD;
             or hinder completion of the study&#xD;
&#xD;
          -  Patients who are currently enrolled in a clinical trial or who received an&#xD;
             investigational study drug within 180 days of screening.&#xD;
&#xD;
          -  Subjects who are not able or willing to comply with the protocol or have any other&#xD;
             condition that would impede compliance or hinder completion of the study, in the&#xD;
             opinion of the investigator.&#xD;
&#xD;
          -  Failure to give informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Schwimmer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UC San Diego</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patricia Ugalde-Nicalo, MD</last_name>
    <phone>619-543-7673</phone>
    <email>pugaldenicalo@health.ucsd.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carissa Carrier, BS</last_name>
    <phone>619-543-2442</phone>
    <email>ccarrier@health.ucsd.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UC San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carissa Carrier</last_name>
      <phone>619-543-2442</phone>
      <email>ccarrier@health.ucsd.edu</email>
    </contact>
    <contact_backup>
      <last_name>Patricia Ugalde Nicalo</last_name>
      <phone>619-543-7673</phone>
      <email>pugaldenicalo@health.ucsd.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 9, 2021</study_first_submitted>
  <study_first_submitted_qc>June 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 1, 2021</study_first_posted>
  <last_update_submitted>July 7, 2021</last_update_submitted>
  <last_update_submitted_qc>July 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Jeffrey B. Schwimmer, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

